Factor XIII (FXIII) is a zymogen essential for normal haemostasis. In inherited FXIII deficiency the majority of cases show absence of the FXIIIa subunit. Molecular analysis of PCR-amplified FXIIIa subunit exonic regions, and of RT-PCR amplified cDNA from six patients with FXIIIa subunit deficiency, from five unrelated families, has revealed 10 sequence changes: three mutations resulting in abnormal splicing of pre-mRNA, one nonsense mutation, one deletion/insertion change, three point mutations producing Val34Leu, Asn60Lys and Arg408Gln changes, and two silent mutations. In three families the patients are homozygous for a specific deficiency causing mutation, and patients from the remaining two families are compound heterozygotes. Understanding the molecular pathology of the disorder provides insights into the structure-function relationships of the various domains within the FXIII protein. From a clinical point of view, it enables direct diagnosis at the DNA level and may aid the development of FXIII analogues to promote wound healing.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.1995.tb05376.xDOI Listing

Publication Analysis

Top Keywords

fxiiia subunit
12
factor xiii
8
molecular basis
4
basis inherited
4
inherited factor
4
deficiency
4
xiii deficiency
4
deficiency identification
4
identification multiple
4
mutations
4

Similar Publications

Background: Germline haplodeficiency (RHD) is associated with thrombocytopenia, platelet dysfunction and predisposition to myeloid malignancies. Platelet expression profiling of a RHD patient showed decreased encoding for the A subunit of factor XIII, a transglutaminase that cross-links fibrin and induces clot stabilization. FXIII-A is synthesized by hematopoietic cells, megakaryocytes and monocytes.

View Article and Find Full Text PDF

Cryo-EM structure of the human native plasma coagulation factor XIII complex.

Blood

January 2025

Arijit Biswas Laboratory, Institute for Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany.

The structure of human coagulation factor XIII (FXIII), a heterotetrameric plasma protransglutaminase that covalently cross-links preformed fibrin polymers, remains elusive until today. The heterotetrameric complex is composed of 2 catalytic FXIII-A and 2 protective FXIII-B subunits. Structural etiology underlying FXIII deficiency has so far been derived from crystallographic structures, all of which are currently available for the FXIII-A2 homodimer only.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the activation and stability of factor XIII subunit FXIII-A, focusing on its unique activation peptide (AP) and how specific mutations affect its function.
  • Recombinant FXIII-A AP variants were created to analyze their role in thrombin activation and transglutaminase activity, using techniques like SDS-PAGE and mass spectrometry for assessment.
  • Key findings highlight that certain mutations to the activation peptide impair FXIII-A stability and activation, indicating that specific amino acid interactions are essential for its functionality in the coagulation process.
View Article and Find Full Text PDF

Development and Epitope Mapping of Seven Mouse Anti-Human Coagulation Factor XIII-B Subunit Monoclonal Antibodies.

Monoclon Antib Immunodiagn Immunother

October 2024

Department of Molecular Patho-Biochemistry and Patho-Biology, School of Medicine, Yamagata University, Yamagata, Japan.

Article Synopsis
  • Coagulation factor XIII (FXIII) is crucial for clot stability, and a deficiency can lead to severe bleeding risks, prompting researchers to immunize mice to create monoclonal antibodies against its B subunit (FXIII-B).
  • Seven mouse monoclonal antibodies were identified, with one (mAb 5-6C) inhibiting fibrin cross-linking while maintaining FXIII's activity, targeting a specific domain that facilitates FXIII-A's interaction with fibrin.
  • The study also introduced a prototype immunochromatography test for measuring FXIII-B levels and detection of autoantibodies, indicating that these antibodies could have significant clinical applications, including potential thrombosis treatment.
View Article and Find Full Text PDF

Transglutaminase mediates the hardening of fish egg envelope produced by duplication of factor XIIIA gene during the evolution of Teleostei.

J Biochem

December 2024

Department of Materials and Life Sciences, Faculty of Science and Technology, Sophia University, 7-1 Kioi-cho, Chiyoda-ku, Tokyo 102-8554, Japan.

Article Synopsis
  • The egg hardening process during fish fertilization is driven by an enzyme called transglutaminase (hTGase), which undergoes processing after fertilization.
  • Researchers isolated a specific version of this enzyme (Rt-hTGase) from rainbow trout eggs, finding that the unprocessed form is 80 kDa and the processed form is 55 kDa, both sharing similar amino acid sequences.
  • The study indicates that the C-terminal processing of Rt-hTGase does not enhance its activity, but it may enable better interaction with egg envelope proteins, facilitating the hardening process.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!